Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silexion Therapeutics ( (SLXN) ) has shared an announcement.
On July 28, 2025, Silexion Therapeutics Corp implemented a 1-for-15 reverse share split of its ordinary shares, following approval from shareholders at the company’s annual general meeting earlier that month. This adjustment, which began trading on July 29, 2025, also led to retroactive changes in the company’s 2024 financial statements, reflecting the reduced number of shares and increased share price. Despite these changes, the company faces substantial doubt about its ability to continue as a going concern due to recurring operational losses and cash outflows.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Average Trading Volume: 91,377
Technical Sentiment Signal: Sell
Current Market Cap: $5.47M
See more data about SLXN stock on TipRanks’ Stock Analysis page.